Patients & CaregiversHealthcare Professionals - Opens new windowWorldwide - Opens new window
Quick Find - Click to open on a page
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
Contact us Contact Newsroom
Podcasts Podcast
RSS RSS

Product News
These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

CANCIDAS® (caspofungin acetate)
Acrobat PDF file Full Prescribing Information
05 Aug 2008  FDA Approves Expanded Label for CANCIDAS® (caspofungin acetate) as the First and Only Echinocandin Therapy for the Treatment of Pediatric Patients (3 months and older) with Indicated Fungal Infections
 

Gardasil® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
20 Aug 2008  Merck Comments on New England Journal of Medicine article by J. Kim and S. Goldie
 
08 Jul 2008  Merck Responds to Questions about Adverse Events Reported following Vaccination with GARDASIL®
 
25 Jun 2008  Merck & Co., Inc Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in Women Ages 27 through 45
 
19 Mar 2008  Supplemental Application for GARDASIL®, Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
 

ISENTRESS™ (raltegravir)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
05 Aug 2008  ISENTRESS® (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naïve HIV-Infected Patients When Taken With Other Anti-HIV Medicines
 
23 Jul 2008  New England Journal of Medicine Reports ISENTRESS® (raltegravir), Merck's First in Class Integrase Inhibitor, Suppressed HIV-1 Viral Load and Increased CD4 Cell Counts through 48-Weeks in Treatment-Experienced Adult Patients When Taken
 

Janumet™ (sitagliptin/metformin HCl) tablets
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
24 Apr 2008  Two Merck Medicines Recommended for Approval in the European Union
 

Januvia™ (sitagliptin)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
09 Jun 2008  A New Analysis Released at ADA: Lower Risk of Symptomatic Hypoglycemia with JANUVIA™ (sitagliptin) Compared to Glipizide on a Background of Metformin in Patients with Type 2 Diabetes
 
07 Jun 2008  New Data Released at Major Diabetes Meeting on Initial Combination Therapy with JANUVIA™ (sitagliptin), Merck's Diabetes Medicine, and Metformin through Two Years of Treatment
 

RotaTeq® (rotavirus vaccine, live, oral, pentavalent)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
25 Jun 2008  CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ®, Merck's Rotavirus Vaccine
 

SINGULAIR® (montelukast)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
27 Mar 2008  Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR™)
 

VYTORIN™ (ezetimibe/simvastatin)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
30 Mar 2008  Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study
 
28 Mar 2008  Statement on IMPROVE-IT Study
 

Zostavax® [Zoster Vaccine Live(Oka/Merck)]
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
15 May 2008  CDC Recommends ZOSTAVAX®, Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
 

top
Printer Friendly Page
 
Contact Merck Site Map Privacy Policy Terms of Use Copyright 1995-2008 Merck & Co., Inc.